FrancophonIA/ELRC3.0 huggingface dataset:
English: The difference in blood pressure increase as compared to placebo was largest in the middle dose group (6.70 mm Hg middle dose vs. 5.38 mmHg high dose).
Maltese: Id-differenza fiż-żieda fil-pressjoni tad-demm kif imqabbla ma' plaċebo kienet l-ikbar fil-grupp tan-nofs (6.70 mm Hg doża tan-nofs vs. 5.38 mmHg doża għolja).
English: The clinical relevance of this effect is unknown.
Maltese: Ir-rilevanza klinika ta' dan l-effett mhix magħrufa.
English: Pregnancy and breast-feeding
Maltese: Anemija, tromboċitopenija
English: Cozaar 100 mg filmdragerade tabletter United Kingdom COZAAR 50 MG FILM-COATED TABLETS United Kingdom COZAAR 25 MG FILM-COATED TABLETS United Kingdom COZAAR 100MG FILM-COATED TABLETS Iceland
Maltese: Il-Ġermanja PINZAAR 100 mg Filmtabletten Il-Ġermanja PINZAAR 50 mg Filmtabletten Il-Ġermanja LORZAAR VARIPHARMSTART 12,5 mg Filmtabletten
English: The Cozaar 25 mg tablets also may contain Carnauba wax (E903), Titanium dioxide (E171).
Maltese: Il-pilloli ta' 25 mg Cozaar jista' jkun fihom ukoll Carnauba wax (E903), Titanium dioxide (E171).
English: During administration of Losartan, removal of the angiotensin II negative feedback on renin secretion leads to increased plasma renin activity (PRA).
Maltese: Waqt l-għoti ta' Losartan, it-tneħħija tar-rispons negattiv ta' angiotensin II fuq t-tnixxija ta' renin għandha twassal għal żieda fl-attività ta' renin fil-plażma (PRA - plasma renin activity).
English: The pharmacokinetics of losartan and its active metabolite are linear with oral losartan potassium doses up to 200 mg.
Maltese: Il-farmakokinetiċi ta' losartan u l-metabolit attiv tiegħu huma linejari b'dożi sa 200 mg losartan potassium meħuda mill-ħalq.
English: Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Maltese: L-użu flimkien ta' antagonisti ta' angiotensin II jew dijuretiċi u NSAIDs jista' jwassal għal riskju ogħla jew tiħżin tal-funzjoni renali, li jinkludi l-possibilità ta' insuffiċjenza renali akuta, u żieda ta' potassju fis-serum, speċjalment f'pazjenti b'funzjoni renali eżistenti minn qabel dgħajfa.
English: The Cozaar 50 mg tablets also may contain Carnauba wax (E903), Titanium dioxide (E171).
Maltese: Il-pilloli ta' 50 mg Cozaar jista' jkun fihom ukoll Carnauba wax (E903), Titanium dioxide (E171).
English: Cozaar may be administered with other antihypertensive agents (e.g. diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycemic agents (e.g. sulfonylureas, glitazones and glucosidase inhibitors).
Maltese: Cozaar jista' jiġi mogħti ma' mediċini ta' kontra l-pressjoni għolja oħrajn (eż., dijuretiċi, impedituri tal-kanali tal-kalċju, impedituri alfa- jew beta- u mediċini li jaġixxu b'mod ċentrali) kif ukoll ma' l-insulina u mediċini ipogliċemiċi komuni oħra (eż. sulfonylureas, glitazones u impedituri ta' glucosidase).
English: The dose should generally be titrated at weekly intervals (i.e. 12.5 mg daily, 25 mg daily, 50 mg daily) to the usual maintenance dose of 50 mg once daily, as tolerated by the patient.
Maltese: 12.5 mg kuljum, 25 mg kuljum, 50 mg kuljum) għal doża ta' manteniment ġenerali ta' 50 mg darba kuljum, kif ittolerata mill-pazjent.
English: 21 film-coated tablets of 12.5 mg and 14 film-coated tablets of 50 mg losartan potassium.
Maltese: 21 pillola miksija b'rita ta' 12.5 mg u 14-il pilloli miksija b'rita ta' 50 mg losartan potassium.
English: As with other drugs that block angiotensin II or its effects, concomitant use of other drugs which retain potassium (e.g. potassium-sparing diuretics: amiloride, triamterene, spironolactone) or may increase potassium levels (e.g. heparin), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium.
Maltese: Bħal fil-każ ta' mediċini oħra li jimblokkaw angiotensin II jew l-effetti tiegħu, l-użu fl-istess ħin ta' mediċini oħra li jiristrinġu l-potassju (eż. dijuretiċi li ma jinkoraġixxux it-tnixxija ta' potassju fl-urina: amiloride, triamteren, spironolactone) jew li jistgħu jżidu l-livelli ta' potassju (eż. eparina), supplimenti tal-potassju jew sostituti ta' l-imluħa li fihom il-potassju jistgħu jwasslu għal żieda tal-potassju fis-serum.
English: The combination of losartan with a beta-blocker should be used with caution (see section 5.1).
Maltese: Il-kombinazzjoni ta' losartan ma' beta-blocker għandha tintuża b'kawtela (ara sezzjoni 5.1)
English: Respiratory, thoracic and mediastinal disorders: not known: cough
Maltese: Disturbi respiratorji, toraċiċi u medjastinali:
English: 21 film-coated tablets of 12.5 mg and 7 film-coated tablets of 50 mg losartan potassium.
Maltese: 21 pillola miksija b'rita ta' 12.5 mg u 7 pilloli miksija b'rita ta' 50 mg losartan potassium.
English: In the LIFE study an additional benefit was noted with regards to stroke for the losartan based strategy, and effects were similar with regard to MI and CV mortality, indicating that the demonstrated beneficial effect of beta-blockade on CV morbidity and mortality in general was also present for losartan.
Maltese: Fl-istudju LIFE kien innotat benefiċċju addizzjonali fir-rigward ta' attakk ta' puplesija għall-istrateġija bbażata fuq losartan, u l-effetti kienu simili fir-rigward talmortalità MI u KV.
English: Doses above 1.4 mg/ kg (or in excess of 100 mg) daily have not been studied in paediatric patients.
Maltese: Dożi ta' aktar minn 1.4 mg/kg (jew b'aktar minn 100 mg) kuljum ma ġewx studjati f'pazjenti tfal.
English: The use of losartan is not recommended in patients with severe hepatic impairment (see section "Do not take losartan").
Maltese: L-użu ta' losartan mhux rakkomandat f'pazjenti li għandhom indeboliment epatiku sever (ara sezzjoni “Tużax losartan”.).
English: Hypertension
Maltese: FARMAĊEWTIKU
English: General disorders and administration site conditions: common: asthenia/fatigue
Maltese: Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata: komuni: astenja/għeja
English: • debility,
Maltese: Ipersensittività;
English: • fatigue,
Maltese: • stitikezza qawwija,
English: Losartan is not recommended in children with glomerular filtration rate < 30ml/ min/ 1.73 m2as no data are available (see section 4.2).
Maltese: Mhuwiex irrakkomandat fi tfal b'rata ta' filtrazzjoni glomerulari < 30 ml/ min / 1.73 m2, minħabba li ma hemm l-ebda tagħrif disponibbli (ara wkoll sezzjoni 4.4).
English: Vascular disorders: common: hypotension
Maltese: Disturbi vaskulari: komuni: pressjoni baxxa
English: Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Maltese: Stenosi tal-valv aortiku u mitrali, kardjomijopatija ipertrofika ostruttiva.
English: In the treatment of heart failure, losartan is usually combined with a diuretic (medicine that increases the amount of water that you pass out through your kidneys) and/or digitalis (medicine that helps to make the heart stronger and more efficient) and/or a beta-blocker .
Maltese: Fit-trattament ta' insuffiċjenza kardijaka, losartan ġeneralment jiġi kkombinat ma' dijuretiku (mediċina li żżid l-ammont ta' ilma li int tgħaddi mill-kliewi) u/jew digitalis (mediċina li tgħin lil qalbek tkun aktar b'saħħitha u aktar effiċjenti) u/jew imblokkatur beta.
English: • very rapid and irregular heartbeat (artrial fibrillation) brain attack (stroke),
Maltese: • qalb tħabbat bil-qawwi u b'mod irregolari (fibrilazzjoni artrijali) attakk fil-moħħ (puplesija)
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors.
Maltese: Żjidiet riversibbli fil-konċentrazzjonijiet tal-litju fis-serum u tossiċità ġew irrapportati waqt it-teħid ta' litju u impedituri ACE flimkien.
English: Cozaar, Cozaar 12,5 mg
Maltese: Cozaar, Cozaar 12,5 mg Il-Finlandja Cozaar Franza
English: Importantly, an ongoing study (HEAAL) comparing 50mg with 150mg losartan in patients with heart failure, may give relevant information on the dosing issue and address other open issues such as the negative results observed in patients on beta-blockers and losartan.
Maltese: Importanti huwa l-fatt li studju li qiegħed isir bħalissa (HEAAL) li jqabbel 50mg ma' 150mg losartan f'pazjenti b'falliment tal-qalb, jista' jagħti tagħrif relevanti fuq ilkwistjoni tad-dożaġġ u jindirizza kwistjonijiet miftuħin oħrajn bħalma huma riżultati negattivi osservati f'pazjenti fuq imblokkaturi-beta u losartan.
English: Each Cozaar 50 mg Tablet contains 50 mg of losartan (as potassium salt).
Maltese: Kull Pillola ta' 50 mg Cozaar fiha 50 mg ta' losartan (bħala mluħa tal-potassju).
English: Following oral administration, plasma concentrations of losartan and its active metabolite decline polyexponentially with a terminal half-life of about 2 hours and 6-9 hours, respectively.
Maltese: Wara l-għoti mill-ħalq, il-konċentrazzjonijiet fil-plażma ta' losartan u l-metabolit attiv tiegħu jonqsu b'mod poliesponenzjali b'half-life terminali ta' madwar sagħtejn u 6-9 sigħat, rispettivament.
English: As a consequence of inhibiting the renin-angiotensin system, changes in renal function including renal failure have been reported (in particular, in patients whose renal function is dependent on the renin angiotensin aldosterone system such as those with severe cardiac insufficiency or pre-existing renal dysfunction).
Maltese: Bħala konsegwenza ta' l-impediment tas-sistema renin-angiotensin, bidliet fil-funzjoni renali li jinkludi insuffiċjenza renali ġew irrapportati (b'mod partikolari f'pazjenti li l-funzjoni renali tagħhom tiddependi fuq is-sistema ta' renin angiotensin aldosterone bħal dawk li għandhom insuffiċjenza kardijaka severa jew disturbi fil-funzjonament renali li kienu jeżistu minn qabel).
English: The most likely symptoms, depending on the extent of overdose, are hypotension, tachycardia, possibly bradycardia.
Maltese: Is-sintomi li x'aktarx jimmanifestaw irwieħhom, skond is-severità tad-doża eċċessiva, huma pressjoni baxxa, takikardja u possibilment bradikarja.
English: Concomitant use of losartan and ACE-inhibitors has shown to impair renal function.
Maltese: La Losartan u lanqas il-metabolit attiv ma jistgħu jiġu eliminati b'emodijaliżi.
English: Belgium Merck Sharp & Dohme BVChaussée de Waterloo 1135
Maltese: Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 - B-1180 Brussels, Il-Belġju
English: Following oral and intravenous administration of 14C-labeled losartan potassium, circulating plasma radioactivity primarily is attributed to losartan and its active metabolite.
Maltese: Wara l-għoti mill-ħalq u ġol-vina ta' losartan potassium ittikkettat b'14C, ir-radjoattività prinċipali fiċ-ċirkolazzjoni hija attribwita għal losartan u l-metabolit attiv tiegħu.
English: HDPE bottles of 100 or 300 tablets.
Maltese: Fliexken ta' l-HDPE b'100 jew 300 pillola.
English: The following side effects have been reported with Cozaar:
Maltese: L-effetti sekondarji li ġejjin ġew irrapportati b' Cozaar:
English: Losartan is not recommended for use in children under 6 years old, as limited data are available in these patient groups.
Maltese: Losartan mhuwiex irrakkomandat għal użu fi tfal taħt l-età ta' 6 snin, minħabba li hemm tagħrif limitat f'dawn il-gruppi ta' pazjenti
English: The antihypertensive effect of Cozaar was established in a clinical study involving 177 hypertensive pediatric patients 6 to 16 years of age with a body weight > 20 kg and a glomerular filration rate > 30 ml/ min/ 1.73 m2.
Maltese: L-effett kontra l-pressjoni għolja ta' Cozaar kien stabbilit fi studju kliniku li involva 177 pazjent pedjatriku bi pressjoni għolja ta' bejn 6 snin u 16-il sena b'piż korporju > 20 kg u b'rata ta' filtrazzjoni glomerulari > 30 ml/ min/ 1.73 m2. Pazjenti li kienu jiżnu >20kg sa < 50 kg irċievew jew 2.5, 25 jew 50 mg ta' losartan kuljum u pazjenti li kienu jiżnu > 50 kg irċievew jew 5, 50 jew 100 mg ta' losartan kuljum.
English: • muscle and joint pain,
Maltese: • uġigħ fil-muskolu u fil-ġogi,
English: MARKETING AUTHORISATION NUMBER(S) [To be completed nationally]
Maltese: NUMRU(I) TA' L-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ [Għandu jitlesta fil-pajjiż stess]
English: In controlled clinical studies, once-daily administration of Losartan to patients with mild to moderate essential hypertension produced statistically significant reductions in systolic and diastolic blood pressure.
Maltese: Fi studji kliniċi b'kontrolli, l-għoti darba fil-ġimgħa ta' Losartan lil pazjenti bi pressjoni essenzjali għolja minn ħafifa sa moderata ikkaġunat tnaqqis statistikament sinifikanti fil-pressjoni tad-demm sistolika u dijastolika.
English: After careful evaluation, the CHMP considered that this indication is acceptable.
Maltese: Għaldaqstant, is-CHMP ikkunsidra li din hija indikazzjoni aċċettabbli.
English: There is no sufficient therapeutic experience with losartan in patients with heart failure and concomitant severe renal impairment, in patients with severe heart failure (NYHA class IV) as well as in patients with heart failure and symptomatic life threatening cardiac arrhythmias.
Maltese: Hemm esperjenza terapewtika ristretta b'losartan f'pazjenti b'insuffiċjenza kardijaka flimkien ma' indeboliment renali sever f'pazjenti b'insuffiċjenza kardijaka severa (NYHA klassi IV) kif ukoll f'pazjenti b'insuffiċjenza kardijaka u b'arritmiji kardijaċi sintomatiċi li huma ta' theddida għal ħajja.
English: Patients with high blood pressure and type 2 diabetes Treatment usually starts with 50 mg losartan (one tablet Cozaar 50 mg) once a day.
Maltese: It-trattament ġeneralment jibda b'pillola waħda ta' 50 mg losartan (pillola Cozaar 50 mg) darba kuljum.
English: Muscoskeletal and connective tissue disorders: not known: back pain
Maltese: Disturbi muskolu-skeletriċi u tat-tessut konnettiv: mhux magħruf: uġigħ fil-muskoli, uġigħ fil-ġogi
English: The observation of the ELITE I Study, that, compared with captopril, Losartan reduced the mortality risk, was not confirmed in the subsequent ELITE II Study, which is described in the following.
Maltese: L-osservazzjoni ta' l-Istudju ELITE, li, mqabbel ma' captopril, Losartan naqqas ir-riskju ta' mortalità, ma ġiex ikkonfermat fl-Istudju sussegwenti ELITE II, li hu deskritt hawn isfel.
English: The CHMP was concerned that the benefit/risk ratio of this indication could not be adequately established.
Maltese: Is-CHMP kien imħasseb li l-proporzjon bejn il-benefiċċju/riskju ta' din l-indikazzjoni ma setax jiġi stabbilit b'mod adegwat.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <{DD/MM/YYYY}> <{DD month YYYY}>
Maltese: DATA TA' L-EWWEL AWTORIZZAZZJONI/TIĠDID TA' L-AWTORIZZAZZJONI <{JJ/XX/SSSS}> <{JJ xahar SSSS}>
English: Treatment of intoxication
Maltese: TAL-PRODOTT MEDIĊINALI
English: Vascular disorders: not known: orthostatic hypotension
Maltese: Mhux magħruf: pressjoni ortostatika baxxa
English: The CHMP considered that the following contra-indications needed to be included in the SPC for Cozaar in all MSs: Pregnancy and lactation; Severely reduced liver function; Angina pectoris; Myocardial infraction; Cerebrovascular disease; Renal artery stenosis; Kidney transplant patients.
Maltese: Anġina pektoris, Infart majokardjali; Mard ċerebrovaskulari; Stenożi ta' l-arterja renali; Pazjenti bi trapjant tal-kliewi.
English: Losartan selectively blocks the AT1 receptor.
Maltese: Losartan jimblokka b'mod silettiv ir-riċettatur AT1.
English: Increase in the PRA leads to an increase in angiotensin II in plasma.
Maltese: Żieda fil-PRA twassal għal żieda f'angiotensin II fil-plażma.
English: Plasma concentrations of Losartan are not altered in patients with a creatinine clearance above 10 ml/minute.
Maltese: Il-konċentrazzjonijiet ta' Losartan fil-plażma m'humiex mibdula f'pazjenti li għandhom it-tneħħija ta' kreatinina 'l fuq minn 10 ml/minuta.
English: Use in patients with intravascular volume depletion:
Maltese: L-użu f'pazjenti bi zvojtjar tal-volum intravaskulari:
English: Use in patients with hepatic impairment:
Maltese: L-użu f'pazjenti f'indeboliment epatiku:
English: The lowest doses studied, 2.5 mg and 5 mg, corresponding to an average daily dose of 0.07 mg/ kg, did not appear to offer consistent antihypertensive efficacy.
Maltese: Id-dożi l-iktar baxxi studjati, 2.5 mg u 5 mg, li jikkorrespondu għal doża medja ta' kuljum ta' 0.07 mg/ kg, ma dehrux li joffru effikaċja konsistenti kontra l-pressjoni għolja.
English: Losartan should be used with caution in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
Maltese: Losartan għandu jintuża b'kawtela f'pazjenti bi stenosi bilaterali ta' l-arterja renali jew stenosi ta' l-arterja b'kilwa solitarja.
English: In patients with heart failure, with or without renal impairment, there is - as with other drugs acting on the renin-angiotensin system - a risk of severe arterial hypotension, and (often acute) renal impairment.
Maltese: F'pazjenti li għandhom insuffiċjenza tal-qalb, bi jew mingħajr indeboliment renali - bħal fil-każ ta' mediċini oħra li jaħdmu fuq is-sistema renin-angiotensin - hemm riskju ta' pressjoni baxxa fl-arterji severa, u indeboliment renali (ta' spiss akuta).
English: (See section 4.5).
Maltese: (Ara sezzjoni 4.5).
English: Tuberculosis (TB)
Maltese: Tuberkolosi (TB)
English: Succursale de Corsier-sur-Vevey Chemin du Fenil Zone Industrielle B 1804 Corsier-sur-Vevey Switzerland
Maltese: Succursale de Corsier-sur-Vevey Chemin du Fenil Zone Industrielle B 1804 Corsier-sur-Vevey L-Iżvizzera
English: 61352 Bad Homburg v.d.Höhe Germany
Maltese: 61352 Bad Homburg v.d.Höhe
English: Clinical response (CR- 100)
Maltese: Rispons kliniku (CR-100)
English: NA 9.5% 41.5%
Maltese: NA NA 9.5% 41.5%
English: ASDAS inactive disease hs-CRP
Maltese: ASDAS marda inattiva hs-CRP
English: Failure N (%)
Maltese: N Falliment N (%)
English: NA 24.0% 58.9%
Maltese: NA NA 24.0% 58.9%
English: Rhabdomyolysis, systemic lupus erythematosus
Maltese: Rabdomijoliżi, lupus erythematosus sistemiku
English: TREATMENT FAILURE RATE (%)
Maltese: TAL-FALLIMENT TATTRATTAMENT (%)
English: Week 8 and 52
Maltese: Ġimgħa 8 u 52
English: 2-sided p value from log rank test.
Maltese: 2-naħat valur P minn test log rank.
English: Placebo/ MTX
Maltese: Plaċebo/ MTX
English: Concurrent treatment with azathioprine/6-mercaptopurine
Maltese: Trattament flimkien ma' azathioprine/6-mercaptopurine
English: • Made of a heavy-duty plastic;
Maltese: • Magħmul minn plastik heavy-duty;
English: Via delle Magnolie 15 I-70026 Modugno (Bari) Italy
Maltese: Via delle Magnolie 15 I-70026 Modugno (Bari)
English: N/A
Maltese: N/A N/A
English: CI 95% for HR
Maltese: CI 95% għall-HR
English: NA 4.5% 23.2%
Maltese: NA NA 4.5% 23.2%
English: Placebo/MTXAdalimumab/MTX (95% confidence interval b)
Maltese: Plaċebo/MTXAdalimumab/MTX (95% Intervall ta' Konfidenza b)
English: Table 17 Maintenance regimen
Maltese: Tabella 17 Reġim ta' manteniment
English: MTX = methotrexate **p < 0.01, adalimumab versus placebo
Maltese: MTX = methotrexate **p < 0.01, adalimumab kontra l-plaċebo
English: It may harm them, even if their signs of illness are the same as your child's.
Maltese: Dawk li waqfu minħabba raġunijiet oħra għajr ilfalliment tat-trattament kienu ċensurati fi żmien li waqfu.
English: - The active substance is adalimumab.
Maltese: - Is-sustanza attiva hi adalimumab.
English: Label area (Kromeya, dose, expiration date)
Maltese: Parti tat-tikketta (Kromeya, doża, data ta' skadenza)
English: Transparent syringe housing Figure H
Maltese: Kompartament trasparenti tas-siringa Stampa H
English: Total sharp score c
Maltese: Punteġġ Totali Sharp c
English: Study nr-axSpA II
Maltese: Studju nr-axSpA II
English: PGA-F clear/minimal and ≥2-grade improvement (%)
Maltese: PGA-F xejn/minimali u ≥2-grad ta' titjib (%)
English: Figure V
Maltese: Stampa V
English: Placebo Adalimumab 40 mg eow
Maltese: Plaċebo Adalimumab 40 mg eow
English: Age over 65 years
Maltese: Aktar minn 65 sena
English: Table 23 Maintenance regimen
Maltese: Tabella 23 Reġim ta' manteniment
English: MRI sacroiliac joints d,i
Maltese: SPARCCh MRI ġogi sakroiljaċi d,i
English: The corresponding proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.
Maltese: Il-proporzjonijiet li jikkorrispondu ta' pazjenti bl-ebda progressjoni radjografika kienu 31.3%, 23.7% u 36.7% rispettivament.
English: Psoriasis
Maltese: Psorijasi
English: Week 52 open-label
Maltese: 52 Ġimgħa open-label
English: Pulmonary fibrosis
Maltese: Fibrożi tal-pulmun
English: Contents of the pack and other information 7.
Maltese: Kontenut tal-pakkett u informazzjoni oħra 7.
English: Quality of life and physical function
Maltese: Kwalità ta' ħajja u funzjoni fiżika
English: Musculoskeletal and connective tissue disorders
Maltese: Disturbi muskoluskeletrali u tal-connective tissue
English: Study UV II
Maltese: UV I and UV II
English: Psoriatic arthritis and axial spondyloarthritis including ankylosing spondylitis
Maltese: Artrite Psorjatika u axial spondyloarthritis inkluż ankylosing spondylitis
English: Via delle Magnolie 15 Loc. frazione Zona Industriale 70026 - Modugno (BA) Italy
Maltese: Loc. frazione Zona Industriale 70026 - Modugno (BA)
English: Double-blind response at week 68
Maltese: Double-blind Rispons f'Ġimgħa 68
English: GI haemorrhage, dyspepsia, gastroesophageal reflux disease, sicca syndrome
Maltese: Emorraġija gastrointestinali, dispepsja, mard ta' reflux gastro-esofagali sindromu sikka
English: PGA: Clear/minimal a, b a p<0.001 adalimumab vs. placebo b p<0.001 adalimumab vs. methotrexate c p<0.01 adalimumab vs. placebo d p<0.05 adalimumab vs. methotrexate
Maltese: PGA: Xejn/minimali a, b a p<0.001 adalimumab vs. plaċebo b p<0.001 adalimumab vs. methotrexate c p<0.01 adalimumab vs. plaċebo d p<0.05 adalimumab vs. methotrexate
English: Step 1
Maltese: Stadju 1
English: Usually, Kromeya is used with methotrexate.
Maltese: Ġeneralment, Kromeya jintuża ma' methotrexate.
English: At week 12 and week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed data approach.
Maltese: F'ġimgħa 12 u ġimgħa 24, ir-rispons PedACR30 kien ta' 93.5% u 90.0% rispettivament meta intużat is-sitema ta' informazzjoni osservata.
English: Figure 1: Kaplan-Meier curves summarizing time to flare in study nr-axSpA II
Maltese: Figura 1: Sommarju tal-kurvi Kaplan-Meier tal-ħin tal-flare fi studju nr-axSpA II
English: Patients received adalimumab 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1 - 0.4 mg/kg weekly (up to 25 mg).
Maltese: Pazjenti rċevew adalimumab 0.8 mg/kg eow (sa 40mg), 0.4 mg/kg eow (sa 20 mg), jew methotrexate 0.1 - 0.4 mg/kg kull ġimgħa (sa 25 mg).
English: Erythema multiforme Stevens-Johnson syndrome angioedema cutaneous vasculitis lichenoid skin reaction
Maltese: Erythema multiforme sindromu ta' Stevens-Johnson angioedema vaskulite tal- ġilda reazzjoni tal-lichenoid fil-ġilda
English: 15 kg to < 30 kg
Maltese: 15 kg sa < 30 kg
English: Lymphoma**, solid organ neoplasm (including breast cancer, lung neoplasm and thyroid neoplasm), melanoma**
Maltese: Limfoma**, neoplażmi fl-organi solidi (li jinkludu kanċer tas-sider, neoplażma fil-pulmun u neoplażma fit-tirojde), melanoma**
English: Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Maltese: Insuffiċjenza tal-qalb minn moderata sa severa (NYHA klassi III/IV) (ara sezzjoni 4.4).
English: Fertility
Maltese: Fertilita
English: 10 kg to < 30 kg
Maltese: 10 kg sa < 30 kg
English: Erosion score JSN
Maltese: Punteġġ talerożjoni Punteġġ JSN
English: Analysis treatment
Maltese: Analiżi trattament